Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ziresovir (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Proof of concept
  • Acronyms VICTOR
  • Sponsors Ark Biosciences

    • Most Recent Events

    • 08 Jan 2020 According to an Ark Biosciences media release, updates from this study will be presented at the JP Morgan Healthcare Conference on January 15th 2020.
    • 05 Nov 2019 Results published in Ark Bioscience Media Release
    • 05 Nov 2019 According to Ark Biosciences media release, detailed clinical results will be published and reported at medical conferences in due course

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top